TransMedics Group, Inc.TMDXNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating

Buy

10 analysts·Moderate coverage

80%

Rating Distribution

Strong Buy

00%

Buy

880%

Hold

220%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 9% higher.

Bear Case

$135.00

-1%

Consensus

$148.17

+9%

Bull Case

$166.00

+22%

Price Range10 analysts

Low

Consensus

High

$135.00

$166.00

Current Target

Current Price

$135.72

Upside to Target

$12.45

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$2.89(9 analysts)

P/E50x

Current: 50.5x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+17.50%

EPS+24.25%

FY2028

Rev+13.71%

EPS+12.28%

FY2029

Rev+16.34%

EPS+14.09%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+165.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 17, 2025Canaccord Genuity

TransMedics price target raised to $148 from $147 at Canaccord

Target:$148.00

+18.4%from $125.04

Dec 8, 2025Needham

TransMedics price target raised to $166 from $148 at Needham

Target:$166.00

+21.6%from $136.51

Dec 2, 2025Morgan Stanley

TransMedics price target raised to $135 from $123 at Morgan Stanley

Target:$135.00

-10.3%from $150.42

Oct 30, 2025Piper Sandler

TransMedics price target lowered to $140 from $145 at Piper Sandler

Target:$140.00

+4.2%from $134.32

Oct 30, 2025Canaccord Genuity

TransMedics Group (TMDX) PT Raised to $147 at Canaccord Genuity

Target:$147.00

+9.4%from $134.32

Oct 23, 2025Needham

TransMedics upgraded to Buy from Hold at Needham

Target:$148.00

+23.8%from $119.54

Oct 13, 2025Jefferies

TransMedics initiated with a Buy at Jefferies

Target:$145.00

+35.1%from $107.29

Oct 7, 2025Evercore ISI

TransMedics added to 'Tactical Underperform' list at Evercore ISI

Target:$155.00

+36.0%from $113.93

Dec 11, 2024Robert W. Baird

TransMedics price target lowered to $120 from $150 at Baird

Target:$120.00

+78.1%from $67.36

Dec 11, 2024Piper Sandler

TransMedics price target lowered to $90 from $110 at Piper Sandler

Target:$90.00

+33.6%from $67.36

Oct 29, 2024Robert W. Baird

TransMedics Group (TMDX) PT Lowered to $150 at Baird

Target:$150.00

+69.1%from $88.70

Oct 29, 2024Canaccord Genuity

TransMedics Group (TMDX) PT Lowered to $109 at Canaccord Genuity

Target:$109.00

-13.7%from $126.24

Oct 29, 2024Needham

TransMedics Group (TMDX) PT Lowered to $109 at Needham

Target:$109.00

-13.7%from $126.24

Oct 29, 2024Oppenheimer

TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer

Target:$125.00

-1.0%from $126.24

Sep 23, 2024Robert W. Baird

TransMedics initiated with an Outperform at Baird

Target:$200.00

+25.4%from $159.50

Sep 4, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on TransMedics Group (TMDX)

Target:$180.00

+13.6%from $158.42

Aug 21, 2024Needham

TransMedics initiated with a Buy at Needham

Target:$208.00

+25.2%from $166.18

Aug 1, 2024Canaccord Genuity

TransMedics price target raised to $169 from $117 at Canaccord

Target:$169.00

+3.0%from $164.02

Aug 1, 2024Oppenheimer

TransMedics price target raised to $200 from $125 at Oppenheimer

Target:$200.00

+40.6%from $142.26

Jul 15, 2024Morgan Stanley

TransMedics price target raised to $145 from $104 at Morgan Stanley

Target:$145.00

+2.0%from $142.19

Jul 15, 2024Piper Sandler

TransMedics price target raised to $170 from $120 at Piper Sandler

Target:$170.00

+19.6%from $142.19

Jun 3, 2024Stephens

Stephens Starts TransMedics Group (TMDX) at Overweight

Target:$151.00

+13.0%from $133.63

Jan 6, 2023Morgan Stanley

Morgan Stanley Maintains Equal-Weight on TransMedics Group, Raises Price Target to $63

Target:$63.00

+10.5%from $57.02

Aug 3, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on TransMedics Group, Raises Price Target to $37

Target:$37.00

-4.2%from $38.63

Aug 2, 2022Oppenheimer

Oppenheimer Maintains Outperform on TransMedics Group, Raises Price Target to $45

Target:$45.00

+18.5%from $37.99

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance